|
TCP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.21819995494377E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.13860000048061E-07 |
| Normal-vs-Stage2 |
4.759700E-04 |
| Normal-vs-Stage3 |
4.94190000033257E-09 |
| Normal-vs-Stage4 |
2.00679999995401E-06 |
| Stage1-vs-Stage2 |
9.283000E-01 |
| Stage1-vs-Stage3 |
2.159600E-02 |
| Stage1-vs-Stage4 |
2.936200E-01 |
| Stage2-vs-Stage3 |
1.068440E-01 |
| Stage2-vs-Stage4 |
4.160000E-01 |
| Stage3-vs-Stage4 |
4.091200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.80409997841258E-09 |
| Normal-vs-AfricanAmerican |
1.938220E-02 |
| Normal-vs-Asian |
1.516690E-03 |
| Caucasian-vs-AfricanAmerican |
2.021800E-01 |
| Caucasian-vs-Asian |
1.638440E-01 |
| AfricanAmerican-vs-Asian |
8.329000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.17170000035749E-07 |
| Normal-vs-Female |
3.16160000402022E-08 |
| Male-vs-Female |
5.281800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.92238999999761E-05 |
| Normal-vs-Age(41-60Yrs) |
1.06030000335267E-08 |
| Normal-vs-Age(61-80Yrs) |
6.0641999977129E-08 |
| Normal-vs-Age(81-100Yrs) |
1.575980E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.204100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.396630E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.211600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.760400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.602200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.057000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.304400E-02 |
| Classical-VS-Follicular |
1.685970E-02 |
| Classical-VS-Other |
5.736400E-01 |
| Classical-VS-Normal |
5.54300000010777E-07 |
| Tall-VS-Follicular |
7.037800E-01 |
| Tall-VS-Other |
5.982600E-01 |
| Tall-VS-Normal |
3.32800000002464E-06 |
| Follicular-VS-Other |
7.732000E-01 |
| Follicular-VS-Normal |
2.12909999963706E-07 |
| Other-VS-Normal |
3.977900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.27250000326163E-08 |
| Normal-vs-N1 |
6.27330000169124E-08 |
| N0-vs-N1 |
1.555380E-01 |
|
|
